ArticleCVIR endovascular2025
One-size-fits-all strategy in carotid artery treatment using CGuard stent, feasibility and clinical pilot study.
Article in CVIR endovascular, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Endovascular treatment strategies in highly-calcified carotid stenoses.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeConventionally, the treatment of carotid artery disease customizes stents to the vessel diameter. The design of the CGuard stent and its nitinol shape memory allow for a wide operational range and minimal residual radial force. This pilot study assesses the feasibility and clinical outcomes of the 10-mm CGuard stent in a one-size-fits-all sizes protocol. MATERIALS AND
methodsThe study is a multicenter, prospective cohort study involving 226 consecutive patients with symptomatic or asymptomatic carotid artery stenosis, with an indication for revascularization. All patients received the 10-mm CGuard stent, irrespective of the carotid artery reference diameter, and were grouped into three categories based on the reference vessel diameter. Endpoints included procedural success and incidence of major adverse cardiovascular events (MACE) at 30 days and 1 year.
resultsThe study achieved 100% technical success, with an average residual stenosis of 8.41%. Clinical success was 98.7%. During in-hospital observation, one patient experienced a major ipsilateral stroke (0.4%), and two patients had transient ischemic attacks (TIAs) (0.8%). At the 30-day follow-up, there were one death and one case of re-occlusion which was asymptomatic. No differences between the three groups were found regarding technical or procedural success, residual stenosis, complications, TIAs, MACEs, or patency rates. No events occurred between the 30-day and 1-year follow-up, maintaining the MACE rate at 1.5%. ICA and ECA patency rates at 1 year were 99% and 99.4%, respectively, indicating mid-term treatment effectiveness.
conclusionThis pilot study demonstrates that the one-size-fits-all approach using a 10-mm CGuard stent to treat carotid artery stenosis provides minimal residual radial force with optimal stent apposition. The one-size-fits-all approach with CGuard stent is feasible, safe, and effective. Further studies for confirmation are guaranteed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.